Pfizer Inc. is one of the world's leading biopharmaceutical companies, discovering and developing medicines and vaccines across a wide range of therapeutic areas. For Canadian investors, Pfizer stock is accessible through multiple listings, including Canadian Depositary Receipts (CDRs) on the Toronto Stock Exchange. The company has a long history dating back to 1849 and is known for its significant portfolio of products, from cardiovascular treatments to vaccines. Understanding Pfizer's business segments, dividend history, and the ways Canadians can invest is key for those considering adding this healthcare giant to their portfolio.
What Pfizer Does
Pfizer Inc. is a global biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, distribution, and sale of medicines and vaccines. Its extensive product portfolio spans numerous therapeutic areas, addressing conditions from common illnesses to rare diseases. The company serves a broad customer base including wholesalers, retailers, hospitals, clinics, government agencies, and pharmacies. Pfizer operates a contract manufacturing business and maintains several key collaboration agreements with other pharmaceutical firms such as Bristol-Myers Squibb, Astellas Pharma, Merck KGaA, and BioNTech SE. Its mission involves applying science and global resources to bring therapies to people that help extend and improve their lives.
Pfizer's Main Business Segments and Products
Pfizer organizes its vast portfolio into several key therapeutic areas, each with flagship products. In cardiovascular health and migraine, the company offers Eliquis, Nurtec ODT, Vydura, Zavzpret, and the Premarin family. For infectious diseases, its products include the Prevnar family of vaccines, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba. The company gained widespread recognition for its COVID-19 prevention and treatment products, Comirnaty and Paxlovid, which are part of its broader mRNA and antiviral development efforts.
Pfizer provides medicines and vaccines for chronic immune and inflammatory diseases, including treatments and biosimilars such as Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo. The company also offers products for rare conditions like amyloidosis, hemophilia, and sickle cell disease, including the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin. Furthermore, Pfizer supplies a portfolio of sterile injectable and anti-infective medicines. This portfolio includes products like Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga.
Pfizer's oncology portfolio includes a wide array of biologics, small molecules, immunotherapies, and biosimilars. Important brands in this area are Ibrance, Xtandi, Padcev, Adcetris, Inlyta, and Lorbrena. The portfolio also features Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna. This diverse collection of treatments addresses significant medical needs and supports the company's business.
History and Corporate Background
The company is headquartered in New York, New York, and its Canadian subsidiary, Pfizer Canada ULC, operates as the national arm of the global corporation. The Canadian operation applies Pfizer's resources to the local market and works alongside community partners to help close health equity gaps. The company states that its colleagues work every day to advance wellness, prevention, treatments, and cures for the most feared diseases. A core principle for Pfizer is patient centricity, which involves listening to the patient perspective and acting as partners to deliver meaningful health outcomes with accountability and integrity.
Where Pfizer Stock Trades and Dividend Information
Pfizer's primary listing is on the New York Stock Exchange under the ticker symbol PFE. For Canadian investors, the stock is readily accessible through Canadian Depositary Receipts (CDRs) that trade on the Toronto Stock Exchange. These CDRs, which are often currency-hedged, trade under symbols such as PFE.TO and PFE.NE, providing a convenient way to hold the stock in Canadian dollars. The company pays a quarterly cash dividend, which was $0.43 per share for its U.S.-listed common stock, and this dividend record is a key consideration for income-focused investors. The dividend is paid on the common shares listed in the United States, and holders of the Canadian CDRs would receive a corresponding distribution based on their holdings.
How Canadians Can Hold Pfizer Stock
Canadian investors have several options for adding Pfizer to their investment portfolios. The most direct method is purchasing the U.S.-listed shares (PFE) through a brokerage account that offers access to U.S. markets, which involves dealing in U.S. dollars and may incur currency exchange fees. A more streamlined alternative for many is to buy the Canadian-listed Pfizer CDRs, such as PFE.TO, which represent an interest in the underlying U.S. shares but trade in Canadian dollars on the TSX. These CDR products often offer currency hedging to mitigate exchange rate risk for the investor. Both the U.S. shares and the Canadian CDRs can be held in registered accounts like the Tax-Free Savings Account (TFSA) or the Registered Retirement Savings Plan (RRSP). Holding the U.S.-listed PFE shares directly in an RRSP is particularly efficient from a tax perspective, as U.S. dividend withholding tax is typically waived under the Canada-U.S. tax treaty for holdings in RRSPs, while investors should consult a professional for implications in TFSAs and non-registered accounts.
Key Risks for Investors
Investing in Pfizer, like any pharmaceutical company, carries specific risks tied to the industry. A primary risk is the reliance on a pipeline of new drugs. The failure of a key drug in clinical trials or a delay in regulatory approval can significantly impact future revenue. The company also faces patent expirations on its blockbuster drugs, which can lead to a rapid decline in sales as generic competitors enter the market. Pfizer's revenue, particularly from products like Comirnaty and Paxlovid, demonstrated sensitivity to pandemic-driven demand, highlighting the volatility that can come from products tied to specific health crises. The biopharmaceutical sector is heavily regulated, and changes in healthcare policy, pricing pressures, and reimbursement rules in key markets like the United States and Canada can affect profitability.
Legal risks, including litigation related to product liability or patent infringement, are also ongoing concerns. Furthermore, the success of the company's numerous collaboration agreements, such as those with BioNTech and Bristol-Myers Squibb, is not guaranteed and depends on the continued performance of all partners. Currency exchange rate fluctuations present an additional risk for Canadian investors holding the U.S.-listed shares directly, though this can be mitigated through hedged CDRs. The company's involvement in contract manufacturing also introduces operational and counterparty risks associated with that business line.
Pfizer's Notable Product Launches and Collaborations
Pfizer's growth comes from its own research and development as well as strategic collaborations. The company has established several key partnership agreements with other firms. These collaborations are important for developing and introducing new products. Significant product launches in recent years have also contributed to the company's expansion.
- Collaboration with BioNTech SE: This partnership led to the rapid co-development and global distribution of the Comirnaty COVID-19 mRNA vaccine.
- Collaboration with Bristol-Myers Squibb Company: A long-standing partnership for the co-development and co-commercialization of the blockbuster blood thinner Eliquis.
- Collaboration with Astellas Pharma US, Inc.: Joint work on the development and commercialization of the prostate cancer treatment Xtandi.
- Collaboration with Merck KGaA: An alliance for the development and marketing of the immunotherapy Bavencio for certain cancers.
- Launch of Paxlovid: The company's oral antiviral treatment for COVID-19, which received emergency use authorizations globally.
- Expansion of the Prevnar family: Continuous updates and new approvals for this franchise of pneumococcal vaccines for different age groups.
- Oncology portfolio expansion: The introduction and acquisition of new cancer therapies like Lorbrena, Talzenna, and the acquisition of Trillium Therapeutics' assets.
These partnerships and new product launches are essential for Pfizer to renew its development pipeline. They help generate future revenue, especially as patents on older medicines expire. Additionally, Pfizer is involved in the contract manufacturing business. This activity provides manufacturing support to other companies in the biopharmaceutical industry.
Frequently asked questions
Does Pfizer pay a dividend?
Yes, Pfizer pays a quarterly cash dividend to holders of its common stock. The dividend was $0.43 per share for the U.S.-listed shares. Canadian investors holding the CDRs receive a corresponding distribution. The dividend is a key component of the total return for many long-term investors in the company.
What is Pfizer's stock symbol in Canada?
Pfizer's stock is available in Canada through Canadian Depositary Receipts (CDRs) listed on the Toronto Stock Exchange. The symbols for these currency hedged instruments include PFE.TO and PFE.NE. These CDRs allow investors to trade Pfizer's underlying U.S. equity in Canadian dollars. The primary listing for Pfizer Inc. is on the New York Stock Exchange under the ticker PFE. The company is a global biopharmaceutical firm founded in 1849 and headquartered in New York.
Can I hold Pfizer stock in my TFSA or RRSP?
Yes, Pfizer stock can be held in both a Tax-Free Savings Account (TFSA) and a Registered Retirement Savings Plan (RRSP). Canadian investors can purchase the U.S. listed shares (PFE) or the Canadian listed CDRs (PFE.TO or PFE.NE) within these registered accounts. Holding the U.S. shares directly in an RRSP is a common strategy to avoid U.S. dividend withholding tax. This provides flexibility for Canadian investors seeking exposure to this leading biopharmaceutical company.
What are Pfizer's main products?
Pfizer has a diverse portfolio of medicines and vaccines across multiple therapeutic areas. Key products include the cardiovascular drug Eliquis, the pneumococcal vaccine Prevnar family, and the COVID 19 vaccine Comirnaty and treatment Paxlovid. In oncology, major products are Ibrance, Xtandi, and Padcev. The company also offers treatments for rare diseases like Vyndaqel for amyloidosis and Oxbryta for sickle cell disease. Additionally, it markets products for chronic inflammatory diseases, such as Xeljanz and Enbrel.
What is Pfizer Canada?
Pfizer Canada ULC is the Canadian operation of the global biopharmaceutical company Pfizer Inc. It is responsible for the marketing, distribution, and support of Pfizer's extensive product portfolio within Canada. The subsidiary applies science and global resources to bring therapies to Canadians. Pfizer Canada also works with community partners to improve health equity and create social impact. It operates with a focus on patient centricity, aiming to deliver outcomes that matter to patients and their caregivers.
What are the risks of investing in Pfizer?
Investing in Pfizer carries several risks common to pharmaceutical companies. These include pipeline dependency where new drug candidates can fail in clinical trials. Patent expirations on blockbuster products like Eliquis can lead to increased generic competition and revenue loss. The company faces ongoing regulatory scrutiny and government pricing pressures globally. Furthermore, its financial performance can be volatile due to fluctuating demand for products tied to specific health crises, such as the COVID 19 pandemic.
Sources and further reading
- Pfizer Inc. (PFE.NE) Stock Price, News, Quote & History ca.finance.yahoo.com
- Pfizer Canada: Homepage pfizer.ca
This article explains how things work and is not financial, tax or legal advice. Rules, limits and rates change, so check the current figures with the Canada Revenue Agency, your province or your financial institution before you act.